UBS/CALL/ASTRAZENECA ADR/77/0.1/17.01.25

UBS/CALL/ASTRAZENECA ADR/77/0.1/17.01.25 Stock

DE000UM5GYP3

Market Closed - Boerse Frankfurt Warrants 13:38:44 2024-07-01 EDT
0.66 ^EUR	-5.71%

Current month

-5.71%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart UBS/CALL/ASTRAZENECA ADR/77/0.1/17.01.25

Latest news about ASTRAZENECA PLC

Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology	11-30	PR
New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy	23-04-14	PR
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research	22-10-27	PR
Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer	22-05-13	PR

More news

Quotes 5-day view

Date	Price	Change
24-07-01	0.66	-5.71%
24-06-28	0.7	0.00%
24-06-27	0.7	-9.09%
24-06-26	0.77	-2.53%
24-06-25	0.79	-1.25%

Real-time Boerse Frankfurt Warrants

Last update July 01, 2024 at 01:38 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	UBS
WKN	UM5GYP
ISIN	DE000UM5GYP3
Date issued	2024-05-14
Strike	77 $
Maturity	2025-01-17 (200 Days)
Parity	10 : 1
Emission price	0.64 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.86 €
Lowest since issue	0.66 €
Spread	0.06 €
Spread %	8.22%

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company